The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
From preventive screenings to affordable generics, 2025 reshaped India's health priorities. Discover the key trends that made wellness a daily habit and what it means for 2026.
A Bengaluru software engineer was arrested for allegedly manufacturing synthetic drugs like MDMA in a makeshift home laboratory. Police seized drugs worth lakhs and equipment. Read the shocking details.
Drugs Control Administration officials raided an unlicensed clinic in Karimnagar, seizing illegal steroids and antibiotics. The crackdown highlights the public health risks of unauthorized drug sales. Read more.
Explore the social and economic impact of GLP-1 drugs like Ozempic & Mounjaro in India. A ₹1,000 crore market is poised for massive growth. Share your thoughts.
Zota Health Care secures ₹350 crore from investors via QIP to fund expansion. MS Dhoni & Suniel Shetty join as brand ambassadors. Aim to open 5000+ generic pharmacy stores by 2029.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
India's pharmaceutical industry gears up for a critical 5-year phase from 2026, aiming to become a $500 billion innovation hub by 2047. Learn how it plans to tackle challenges and seize opportunities.
A severe shortage of drug inspectors is hampering enforcement against spurious and adulterated medicines in India. Officials admit the staffing crisis is a major hurdle. Read more on the critical public health issue.
The Indian government is considering data exclusivity for pharma, a move that could delay cheap generic drugs, impact India's global edge, and affect medicine access. Read the full analysis.
Himachal Pradesh reports the highest number of substandard drug samples in India. 49 samples failed quality tests, raising serious concerns about public health and pharmaceutical regulation.
The Indian government mandates a 500-meter distance between Jan Aushadhi Kendras in major cities to protect store viability and ensure access to affordable generic medicines. Learn about the new policy's impact.
The Supreme Court has agreed to hear SAD leader Bikram Singh Majithia's plea for bail in a drugs case. The hearing is scheduled for July 15. Read the latest legal developments.
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Karnataka Assembly passes the Drugs and Cosmetics (Amendment) Bill, 2024, enhancing penalties for spurious drug manufacturers and regulating online pharmacy sales. Learn the key changes.
Karnataka Health Minister Dinesh Gundu Rao announces state will appeal HC order quashing closure of Jan Aushadi Kendras in govt hospitals. Read the full story.
Shark Tank India's Anupam Mittal comments on Ozempic's India launch, its ₹8,800/month price, and the 2026 patent expiry that could 5x the market. Read his take on fitness shortcuts vs. discipline.
Delhi's Drugs Control department sealed a shop & collected 204 samples from 27 wholesale dealers in a major drive against illegal drug trade. Health Minister vows zero tolerance for spurious medicines.
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
WWE Hall of Famer Ric Flair discloses Hulk Hogan turned to street drugs after multiple surgeries left him in unbearable pain. Read the shocking details.
India's drug regulator CDSCO refuses to waive local trials for lenacapavir, blocking access to revolutionary HIV prevention for 25 lakh Indians. Learn why this happens despite drug being manufactured in India.
RGIA Hyderabad becomes frontline in India's fight against hydroponic cannabis smuggling from Southeast Asia. Discover how smugglers are targeting air travelers.
Himachal Pradesh schools partner with police in innovative sports initiative to combat drug abuse among youth. Learn how education and sports create positive alternatives.
Rajesh Bakshi and accomplice Jon-Paul Clark sentenced for attempting to smuggle 40kg heroin into UK. NCA investigation reveals international drug trafficking network.